ACE and hydrops fetalis: Similarly, HFrEF patients on the combination of all three classes of medications: ACE inhibitor/angiotensin II receptor blockers, β-blockers and aldosterone antagonists, had significantly lower 1-year and 5-year all-cause mortality compared with HFrEF patients who were on none or only one class of HF medications (1 year: 17% vs 34%, p=0.023, 5 years: 40% vs 69%, p<0.001).